array:19 [
  "pii" => "X0211699504029833"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2218
    "formatos" => array:3 [
      "EPUB" => 245
      "HTML" => 1569
      "PDF" => 404
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029825"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2395
      "formatos" => array:3 [
        "EPUB" => 236
        "HTML" => 1675
        "PDF" => 484
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "NADPH Oxidación y stress oxidativo en las enfermedades cardiovasculares"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "4"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R. A. CLARK , T. K. EPPERSON , J. VALENTE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R. A. CLARK , T. K. EPPERSON , J. VALENTE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029825?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029825/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029841"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:1-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5161
      "formatos" => array:3 [
        "EPUB" => 241
        "HTML" => 4442
        "PDF" => 478
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Introducci&#243;n</span>"
      "titulo" => "Introducci&#243;n"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; LU&#209;O"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J&#46; LU&#209;O"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029841?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029841/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "&#191;Es el agente o el nivel de presi&#243;n arterial lo que influye en la protecci&#243;n renal de las nefropat&#237;as cr&#243;nicas&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "3"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "F&#46; LOCATELLI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "F&#46; LOCATELLI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOG&#205;A&#46; Vol&#46; XXIV&#46; N&#250;mero Extraordinario &#40;I&#41;&#46; 2004 &#191;Es el agente o el nivel de presi&#243;n arterial lo que influye en la protecci&#243;n renal de las nefropat&#237;as cr&#243;nicas&#63; F&#46; Locatelli Department of Nephrology and Dialysis&#46; Ospedale A&#46; Manzoni&#46; Lecco&#46; Italy&#46; Hypertension is not only an important presenting feature of renal disease and&#44; together with proteinuria&#44; probably a major factor contributing to progression&#44; but also a significant determinant of morbidity and mortality among hemodialysis patients&#46; Over the last decade&#44; a number of trials have been performed to assess the degree of BP reduction needed to achieve reno-protection&#46; The results of the Modification of Diet in Renal Disease &#40;MDRD&#41; Study clearly showed that stricter BP control was capable of slowing CRI progression&#44; compared with BP control that was usual for that time&#46; The patients with higher levels of baseline proteinuria received greater benefits from being assigned to a low BP target&#46; Over recent years it has become clear that not all anti-hypertensive agents are equally effective in slowing CKD progression&#44; and that some have an additional reno-protective effect that seems at least partially independent of BP reduction and is probably linked to their capacity of halting some of the pathogenic mechanisms involved in renal damage&#46; Indeed&#44; several clinical trials have shown that drugs blocking the renin-angiotensin system are more effective in reducing CKD progression compared with other anti-hypertensive drugs in diabetic and nondiabetic nephropathies&#46; However&#44; in the majority of large trials&#44; target and achieved BP values were constantly higher than those nowadays recommended&#46; Moreover&#44; the BP values were often lower in the experimental groups &#40;ACE-I or ATIIRA&#41; compared with the control groups and BP values during 24 hours were not recorded&#46; Although this effect seems to be partially independent of blood pressure &#40;BP&#41; reduction&#44; it is still unclear whether these drugs are really superior to other anti-hypertensive agents when the BP values recommended by the present guidelines are actually achieved&#46; This is particularly true when considering that&#44; in published trials&#44; target and achieved blood pressure values were constantly higher than those nowadays recommended&#46; Furthermore&#44; in the majority of these studies&#44; patients treated with ACE-inhibitors &#40;ACE-I&#41; or Angiotensin II receptor antagonists &#40;ATIIRA&#41; achieved lower BP values than those in control groups and BP values during 24 hours were not recorded&#46; A secondary analysis of the AIPRI data&#44; which has taken into account both the effects of SBP and DBP&#44; at baseline and during follow-up&#44; on the risk of developing the primary composite end-point showed that proteinuria values at baseline and throughout follow-up were the main factors related to the renal outcomes &#40;each g per day greater levels of proteinuria at baseline was associated with an increase of 39&#37; in the relative risk for the primary end-point&#44; each g per day greater levels of proteinuria during follow-up was associated with an increase in the relative risk of 35&#37;&#41;&#46; DBP at baseline &#40;relative risk increase of 6&#37; for each mmHg increase&#41; and SBP changes from baseline throughout follow-up &#40;relative risk increase of 3&#37; for each mmHg increase&#41; were also independently related to the primary end-points&#46; When all of these co-variates were considered&#44; a trend towards independent reno-protection by ACE-I was still present&#44; but without statistical significance &#40;relative risk reduction of 20&#37;&#41;&#46; However&#44; the regression lines of the control and benazepril groups were parallel &#40;P 0&#46;326&#41; and significantly different &#40;P &#60; 0&#46;001&#41;&#44; possibly indicating that the anti-proteinuric effect of ACE-I was independent of the BP control achieved&#46; In conclusion&#44; the reno-protective effect of these agents &#40;ACE-I&#44; ATIIRA&#41; is partially independent of a better BP control&#46; However&#44; caution should be paid in attributing true biological reno-protective properties to drugs just basing on statistical adjustments of BP values&#44; although robustly performed&#44; without being aware of what those BP values actually reflect&#46; 3 "
    "pdfFichero" => "P7-E232-S132-A2962.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/P7-E232-S132-A2962.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029833?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

¿Es el agente o el nivel de presión arterial lo que influye en la protección renal de las nefropatías crónicas?
F. LOCATELLI
Leído
5425
Veces
se ha leído el artículo
2005
Total PDF
3420
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699504029833"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2218
    "formatos" => array:3 [
      "EPUB" => 245
      "HTML" => 1569
      "PDF" => 404
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029825"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2395
      "formatos" => array:3 [
        "EPUB" => 236
        "HTML" => 1675
        "PDF" => 484
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "NADPH Oxidaci&#243;n y stress oxidativo en las enfermedades cardiovasculares"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "4"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R&#46; A&#46; CLARK &#44; T&#46; K&#46; EPPERSON &#44; J&#46; VALENTE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R&#46; A&#46; CLARK &#44; T&#46; K&#46; EPPERSON &#44; J&#46; VALENTE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029825?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029825/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029841"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:1-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5161
      "formatos" => array:3 [
        "EPUB" => 241
        "HTML" => 4442
        "PDF" => 478
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Introducci&#243;n</span>"
      "titulo" => "Introducci&#243;n"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; LU&#209;O"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J&#46; LU&#209;O"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029841?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029841/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "&#191;Es el agente o el nivel de presi&#243;n arterial lo que influye en la protecci&#243;n renal de las nefropat&#237;as cr&#243;nicas&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "3"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "F&#46; LOCATELLI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "F&#46; LOCATELLI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOG&#205;A&#46; Vol&#46; XXIV&#46; N&#250;mero Extraordinario &#40;I&#41;&#46; 2004 &#191;Es el agente o el nivel de presi&#243;n arterial lo que influye en la protecci&#243;n renal de las nefropat&#237;as cr&#243;nicas&#63; F&#46; Locatelli Department of Nephrology and Dialysis&#46; Ospedale A&#46; Manzoni&#46; Lecco&#46; Italy&#46; Hypertension is not only an important presenting feature of renal disease and&#44; together with proteinuria&#44; probably a major factor contributing to progression&#44; but also a significant determinant of morbidity and mortality among hemodialysis patients&#46; Over the last decade&#44; a number of trials have been performed to assess the degree of BP reduction needed to achieve reno-protection&#46; The results of the Modification of Diet in Renal Disease &#40;MDRD&#41; Study clearly showed that stricter BP control was capable of slowing CRI progression&#44; compared with BP control that was usual for that time&#46; The patients with higher levels of baseline proteinuria received greater benefits from being assigned to a low BP target&#46; Over recent years it has become clear that not all anti-hypertensive agents are equally effective in slowing CKD progression&#44; and that some have an additional reno-protective effect that seems at least partially independent of BP reduction and is probably linked to their capacity of halting some of the pathogenic mechanisms involved in renal damage&#46; Indeed&#44; several clinical trials have shown that drugs blocking the renin-angiotensin system are more effective in reducing CKD progression compared with other anti-hypertensive drugs in diabetic and nondiabetic nephropathies&#46; However&#44; in the majority of large trials&#44; target and achieved BP values were constantly higher than those nowadays recommended&#46; Moreover&#44; the BP values were often lower in the experimental groups &#40;ACE-I or ATIIRA&#41; compared with the control groups and BP values during 24 hours were not recorded&#46; Although this effect seems to be partially independent of blood pressure &#40;BP&#41; reduction&#44; it is still unclear whether these drugs are really superior to other anti-hypertensive agents when the BP values recommended by the present guidelines are actually achieved&#46; This is particularly true when considering that&#44; in published trials&#44; target and achieved blood pressure values were constantly higher than those nowadays recommended&#46; Furthermore&#44; in the majority of these studies&#44; patients treated with ACE-inhibitors &#40;ACE-I&#41; or Angiotensin II receptor antagonists &#40;ATIIRA&#41; achieved lower BP values than those in control groups and BP values during 24 hours were not recorded&#46; A secondary analysis of the AIPRI data&#44; which has taken into account both the effects of SBP and DBP&#44; at baseline and during follow-up&#44; on the risk of developing the primary composite end-point showed that proteinuria values at baseline and throughout follow-up were the main factors related to the renal outcomes &#40;each g per day greater levels of proteinuria at baseline was associated with an increase of 39&#37; in the relative risk for the primary end-point&#44; each g per day greater levels of proteinuria during follow-up was associated with an increase in the relative risk of 35&#37;&#41;&#46; DBP at baseline &#40;relative risk increase of 6&#37; for each mmHg increase&#41; and SBP changes from baseline throughout follow-up &#40;relative risk increase of 3&#37; for each mmHg increase&#41; were also independently related to the primary end-points&#46; When all of these co-variates were considered&#44; a trend towards independent reno-protection by ACE-I was still present&#44; but without statistical significance &#40;relative risk reduction of 20&#37;&#41;&#46; However&#44; the regression lines of the control and benazepril groups were parallel &#40;P 0&#46;326&#41; and significantly different &#40;P &#60; 0&#46;001&#41;&#44; possibly indicating that the anti-proteinuric effect of ACE-I was independent of the BP control achieved&#46; In conclusion&#44; the reno-protective effect of these agents &#40;ACE-I&#44; ATIIRA&#41; is partially independent of a better BP control&#46; However&#44; caution should be paid in attributing true biological reno-protective properties to drugs just basing on statistical adjustments of BP values&#44; although robustly performed&#44; without being aware of what those BP values actually reflect&#46; 3 "
    "pdfFichero" => "P7-E232-S132-A2962.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/P7-E232-S132-A2962.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029833?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 4 8 12
2024 Octubre 38 27 65
2024 Septiembre 36 28 64
2024 Agosto 54 62 116
2024 Julio 42 28 70
2024 Junio 60 37 97
2024 Mayo 55 27 82
2024 Abril 36 36 72
2024 Marzo 28 21 49
2024 Febrero 40 34 74
2024 Enero 30 20 50
2023 Diciembre 26 18 44
2023 Noviembre 55 25 80
2023 Octubre 42 30 72
2023 Septiembre 65 29 94
2023 Agosto 46 27 73
2023 Julio 35 25 60
2023 Junio 31 12 43
2023 Mayo 49 30 79
2023 Abril 16 16 32
2023 Marzo 28 21 49
2023 Febrero 20 36 56
2023 Enero 42 29 71
2022 Diciembre 42 39 81
2022 Noviembre 30 25 55
2022 Octubre 31 35 66
2022 Septiembre 34 30 64
2022 Agosto 34 43 77
2022 Julio 31 47 78
2022 Junio 37 36 73
2022 Mayo 20 42 62
2022 Abril 24 45 69
2022 Marzo 48 43 91
2022 Febrero 28 35 63
2022 Enero 30 26 56
2021 Diciembre 36 43 79
2021 Noviembre 21 35 56
2021 Octubre 37 45 82
2021 Septiembre 24 40 64
2021 Agosto 23 38 61
2021 Julio 35 33 68
2021 Junio 18 19 37
2021 Mayo 22 34 56
2021 Abril 57 28 85
2021 Marzo 31 29 60
2021 Febrero 24 21 45
2021 Enero 25 21 46
2020 Diciembre 17 14 31
2020 Noviembre 22 15 37
2020 Octubre 16 15 31
2020 Septiembre 9 10 19
2020 Agosto 33 8 41
2020 Julio 15 9 24
2020 Junio 16 11 27
2020 Mayo 31 18 49
2020 Abril 29 20 49
2020 Marzo 27 16 43
2020 Febrero 29 14 43
2020 Enero 32 18 50
2019 Diciembre 40 23 63
2019 Noviembre 37 10 47
2019 Octubre 24 7 31
2019 Septiembre 18 14 32
2019 Agosto 11 12 23
2019 Julio 19 25 44
2019 Junio 18 10 28
2019 Mayo 13 22 35
2019 Abril 36 23 59
2019 Marzo 16 14 30
2019 Febrero 12 11 23
2019 Enero 20 16 36
2018 Diciembre 37 26 63
2018 Noviembre 53 10 63
2018 Octubre 55 19 74
2018 Septiembre 30 7 37
2018 Agosto 23 10 33
2018 Julio 20 10 30
2018 Junio 15 5 20
2018 Mayo 20 12 32
2018 Abril 21 6 27
2018 Marzo 16 6 22
2018 Febrero 18 6 24
2018 Enero 12 5 17
2017 Diciembre 27 6 33
2017 Noviembre 15 4 19
2017 Octubre 16 5 21
2017 Septiembre 12 5 17
2017 Agosto 13 7 20
2017 Julio 14 5 19
2017 Junio 8 3 11
2017 Mayo 11 7 18
2017 Abril 18 3 21
2017 Marzo 12 4 16
2017 Febrero 14 6 20
2017 Enero 7 3 10
2016 Diciembre 17 4 21
2016 Noviembre 13 4 17
2016 Octubre 10 2 12
2016 Septiembre 23 2 25
2016 Agosto 39 0 39
2016 Julio 56 0 56
2016 Junio 34 0 34
2016 Mayo 85 0 85
2016 Abril 41 0 41
2016 Marzo 39 0 39
2016 Febrero 59 0 59
2016 Enero 60 0 60
2015 Diciembre 68 0 68
2015 Noviembre 59 0 59
2015 Octubre 46 0 46
2015 Septiembre 33 0 33
2015 Agosto 32 0 32
2015 Julio 17 0 17
2015 Junio 16 0 16
2015 Mayo 19 0 19
2015 Abril 7 0 7
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?